Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
49 studies found for:    vedolizumab
Show Display Options
Rank Status Study
1 Recruiting Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
Conditions: Colitis, Ulcerative;   Crohn Disease
Intervention: Drug: Vedolizumab
2 Completed Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
Condition: Healthy
Interventions: Drug: Vedolizumab SC;   Drug: Vedolizumab IV
3 Not yet recruiting Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
Conditions: Colitis, Ulcerative;   Crohn Disease
Intervention: Drug: Vedolizumab
4 Not yet recruiting Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
Conditions: Crohn's Disease;   Ulcerative Colitis;   Inflammatory Bowel Disease
Intervention: Drug: Vedolizumab
5 Withdrawn Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Interventions: Drug: Vedolizumab intravenous injection;   Drug: Vedolizumab subcutaneous injection
6 Recruiting Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Vedolizumab;   Drug: Placebo
7 Recruiting Dose Finding Study of Vedolizumab for Graft-Versus-Host Disease (GvHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Condition: Allogeneic Hematopoietic Stem Cell Transplantation
Intervention: Drug: Vedolizumab
8 Not yet recruiting Vedolizumab Induction May Prevent Celiac Enteritis
Condition: Celiac Disease
Intervention: Drug: Vedolizumab
9 Recruiting Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: Vedolizumab
10 Completed
Has Results
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: vedolizumab
11 Not yet recruiting Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
Condition: ULCERATIVE COLITIS
Interventions: Drug: VEDOLIZUMAB;   Drug: ADALIMUMAB
12 Active, not recruiting Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo
13 Active, not recruiting Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Vedolizumab;   Drug: Vedolizumab placebo
14 Recruiting Vedolizumab Subcutaneous Long-Term Open-Label Extension Study
Conditions: Colitis, Ulcerative;   Crohn Disease
Intervention: Drug: Vedolizumab SC
15 Recruiting Phase 4 Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Condition: Colitis, Ulcerative
Interventions: Drug: Vedolizumab;   Drug: Ciprofloxacin;   Drug: Vedolizumab Placebo
16 Not yet recruiting Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Condition: Crohn Disease
Intervention: Drug: Vedolizumab
17 Recruiting OTIS Vedolizumab Pregnancy Exposure Registry
Conditions: Colitis, Ulcerative;   Crohn's Disease
Interventions: Drug: Vedolizumab;   Biological: Other Biological Agent
18 Recruiting Entyvio (Vedolizumab) Long Term Safety Study
Condition: Ulcerative Colitis and Crohn's Disease
Interventions: Drug: Vedolizumab;   Other: Other Biologic Agents
19 Completed
Has Results
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: vedolizumab;   Other: Placebo
20 Completed
Has Results
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: vedolizumab;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.